PBI Webinar: FVIII & FIX Testing of Emerging Therapies

I (Geo) recommend a May 8, 2024 Precision BioLogic webinar by Chief Scientific Officer Jon Geske, PhD and Marketing Director Ian Burns that compares one-stage clot-based and chromogenic assays when testing for the activity of extended half-life FVIII and FIX concentrates, FVIII mimetics such as emicizumab, RNAi’s such as fitusiran, and the products of FVIII and FIX gene transfer.